TransMedics Current Deferred Revenue from 2010 to 2024

TMDX Stock  USD 78.58  2.54  3.34%   
TransMedics Current Deferred Revenue yearly trend continues to be fairly stable with very little volatility. Current Deferred Revenue is likely to outpace its year average in 2024. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2018-12-31
Previous Quarter
1.4 M
Current Value
2.2 M
Quarterly Volatility
773.9 K
 
Covid
Check TransMedics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TransMedics' main balance sheet or income statement drivers, such as Interest Expense of 11.3 M, Selling General Administrative of 125.5 M or Research Development of 22.2 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 19.64. TransMedics financial statements analysis is a perfect complement when working with TransMedics Valuation or Volatility modules.
  
Check out the analysis of TransMedics Correlation against competitors.

Latest TransMedics' Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of TransMedics Group over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. TransMedics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TransMedics' overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Slightly volatile
   Current Deferred Revenue   
       Timeline  

TransMedics Current Deferred Revenue Regression Statistics

Arithmetic Mean477,203
Geometric Mean318,130
Coefficient Of Variation130.59
Mean Deviation408,752
Median239,000
Standard Deviation623,199
Sample Variance388.4B
Range1.9M
R-Value0.59
Mean Square Error271.4B
R-Squared0.35
Significance0.02
Slope82,569
Total Sum of Squares5.4T

TransMedics Current Deferred Revenue History

20242.1 M
2023M
2022241 K
2021250 K
2020263 K
2019166 K
2018306 K

About TransMedics Financial Statements

TransMedics investors use historical fundamental indicators, such as TransMedics' Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TransMedics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred RevenueM2.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.